![](/img/cover-not-exists.png)
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I. Lang, M.J. Inbar, Z. Kahán, R. Greil, S. Beslija, S.M. Stemmer, B. Kaufman, Z. Zvirbule, G.G. Steger, D. Messinger, T. Brodowicz, C. ZielinskiVolume:
48
Year:
2012
Language:
english
DOI:
10.1016/j.ejca.2012.04.022
File:
PDF, 302 KB
english, 2012